🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  2. gemcitabine

    Yung NA

    Muscle Invasive Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  3. intravenous infusion (IV) of Adebrelimab (ADE)

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  4. ivonescimab

    CERO THERAPEUTICS HOLDINGS, INC.

    pleural mesothelioma

    phase 2 small molecule active

    1 trial

  5. pharmorubicin or pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  6. retinal pigment epithelium transplantation

    The First People's Hospital of Lianyungang

    Dry Age-related Macular Degeneration

    phase 2 mab active

    1 trial

  7. riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Chronic inflammatory demyelinating polyradiculoneuropathy

    phase 2 small molecule active

    1 trial

  8. selinexor

    Karyopharm Therapeutics Inc

    Richter's Transformation

    phase 2 small molecule terminated

    1 trial

  9. selinexor (KPT-330)

    Karyopharm Therapeutics Inc

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  10. standard triple region

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Helicobacter Pylori Infection

    phase 2 small molecule completed

    1 trial

  11. tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric

    phase 2 small molecule active

    1 trial

  12. tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage III

    phase 2 small molecule active

    1 trial

  13. zelicapavir

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule active

    1 trial

  14. 131I-IPA

    Telix Innovations

    Neoplastic Disease

    phase 1 small molecule active

    1 trial

  15. 153Sm-DOTMP

    Telix Innovations

    Bone Pain

    phase 1 small molecule active

    1 trial

  16. 177Lu-DOTA-TLX591

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 mab completed

    1 trial

  17. 177Lu-TLX250 and Peposertib

    Telix Innovations

    Solid Tumor, Adult

    phase 1 other active

    1 trial

  18. 64Cu-DOTA-TLX592

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 small molecule completed

    1 trial

  19. 68-Ga PSMA11

    Telix Innovations

    Prostate Adenocarcinoma

    phase 1 small molecule active

    1 trial

  20. 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

    Telix Innovations

    Soft Tissue Sarcoma

    phase 1 small molecule active

    1 trial

  21. 89Zr-Girentuximab

    Telix Innovations

    Clear Cell Renal Carcinoma

    phase 1 other completed

    1 trial

  22. 89Zr-Girentuximab

    Telix Innovations

    Urothelial Carcinoma

    phase 1 small molecule completed

    1 trial

  23. 89Zr-girentuximab

    Telix Innovations

    Carcinoma, Renal Cell

    phase 1 other completed

    1 trial

  24. A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources